<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=384506&amp;fmt=gif">
Skip to content
Sign Up
    November 10, 2011

    New data released: Trypanosomal phosphodiesterase inhibitors.

    A new public data set has been released from the neglected disease drug discovery team at Northeastern University (Boston, MA) and the Marine Biological Laboratory at Woods Hole, as reported in the Journal of Medicinal Chemistry this week (DOI: 10.1021/jm201148s). This data set consists of a range of established human phosphodiesterase inhibitors, tested for inhibition against the phosphodiesterases B1 and B2 of Trypanosoma brucei.

    The Laboratory for Neglected Disease Drug Discovery at Northeastern University will publically release compound structure and biological activity data as a matter of course immediately upon publication. Research projects primarily employ a target repurposing approach, wherein essential pathogen targets are matched with proven druggable human homologs. The pathogen targets (or the pathogens themselves) are tested for susceptibility to established inhibitors of the human homologs, providing a potential starting point for optimization of new anti-infective agents, or even opportunities for direct repurposing of existing drugs.

    For more information, contact Mike Pollastri at Northeastern University (m.pollastri@neu.edu), or check out the laboratory website: http://www.northeastern.edu/pollastri/.


    Other posts you might be interested in

    View All Posts
    CDD Blog
    8 min   July 22, 2024
    Drug Discovery Industry Roundup with Barry Bunin — July, 22 2024
    Read More
    CDD Blog
    34 min   July 1, 2024
    Critical Data Considerations for All Lifecycle Stages of a Biotech Startup
    Read More
    CDD Vault Snack
    3 min   June 27, 2024
    Vault Snack #24 - New Interface, Features & Infrastructure for the CDD Vault ELN
    Read More